Abstract
Peritoneal mesothelioma (PeM) represents around one fifth to one third of all mesothelioma. The incidence of PeM is approximately one per 1,000,000. Giving the fact of non-specificity of the symptoms, the diagnoses is usually delay. Multimodality treatment with adjuvant chemotherapy and cytoreductive surgery (CRS) and hyper thermic intraperitoneal chemotherapy (HIPEC) improve the long term survival. Herein, this is a presentation of patient diagnosed with peritoneal mesothelioma with a review of literature.
Conflict of Interest
The authors declare no conflict of interest.
Ethical Approval
Not applicable
Data Availability
The datasets used in this study are openly available at [repository link] and the source code is available on GitHub at [GitHub link].
Funding
This work did not receive any external funding.
Cite this article
Related Research
